Upper tract urothelial carcinoma (UTUC) represents a relatively rare, albeit in most cases highly malignant, disease accounting for ∼5--10% of all urothelial carcinomas ([@bib17]). At present, the estimated annual incidence rate of UTUC in western countries is about 2/100.000 inhabitants ([@bib9]; [@bib17]). Up to 60% of UTUCs present invasive at the time of diagnosis compared with only 15--25% of malignant bladder tumours. UTUCs invading the muscle wall are in general considered to represent highly aggressive tumours with an accordingly poor prognosis ([@bib17]). Five-year cancer-specific survival (CSS) rates are \<50% for locally muscle-invasive tumours and even \<10% for locally advanced ones ([@bib5]). According to the recent literature, prognostic factors of paramount importance in UTUC are pathologic (pT) tumour stage and grade ([@bib4]; [@bib18]). Other prognostic factors that were shown to have a significant role in UTUC include lymphovascular invasion and histologic tumour necrosis ([@bib25]). In contrast, the knowledge of preoperatively assessable prognostic factors in UTUC is still limited. Moreover, none of blood- or tissue-based potential biomarkers have fulfilled the clinical and statistical criteria necessary to support their introduction into routine clinical practice in UTUC so far.

There is a growing body of evidence supporting the role of the immune response as an important factor in human cancer development and progression ([@bib2]). Several markers of systemic inflammatory response, such as the pretreatment plasma fibrinogen level, C-reactive protein, neutrophil- or platelet counts, as well as the neutrophil--lymphocyte ratio (NLR), have been shown to represent independent prognostic factors in various human cancer types ([@bib2]; [@bib6]; [@bib7]; [@bib12]; [@bib14], [@bib15]; [@bib21]; [@bib22]; [@bib24]). In particular, the pretreatment NLR might be regarded as an easily measureable and reproducible marker of systemic immune response, having a potential role in renal cell carcinoma as well as in UTUC ([@bib14]). In a recently published report, we were able to confirm the role of pretreatment NLR as an independent prognosticator in UTUC patients ([@bib3]). Regarding routinely measured laboratory parameters, in general only white cell and neutrophil counts, are commonly entered into clinical trial databases; therefore, in an attempt to obviate this problem, [@bib16]) recently implemented a derived score, named the derived neutrophil--lymphocyte ratio (dNLR), which is composed of neutrophil count to (white cell count−neutrophil count). They evaluated the potential prognostic value of the dNLR on cancer outcomes in various human cancer types and were able to demonstrate that the dNLR had similar prognostic value as the established NLR ([@bib16]). More recently, other studies confirmed an independent prognostic value of the dNLR in certain types of cancer; however, they proposed different optimal cutoff values in different types of cancer ([@bib1]; [@bib23]). Thus, we decided to validate the prognostic significance of the pretreatment dNLR in a large European cohort of patients with non-metastatic UTUC with regard to patients\' CSS as well as overall survival (OS).

Materials and Methods
=====================

This retrospective analysis included data from 171 patients of a cohort of 202 consecutive non-metastatic UTUC patients who underwent radical nephroureterectomy or segmental ureterectomy at the Department of Urology at the Medical University of Graz, between September 1990 and July 2012. Thirty-one (15.3%) patients of the whole cohort (*n*=202) could not be included into analyses due to at least one missing laboratory parameter at the time of surgical intervention. To analyse whether there are any differences between the excluded (*n*=31) patients and the actually analysed cases (*n*=171), we compared all available clinicopathological parameters between these two groups. All clinicopathological data were retrieved from medical records at the Department of Urology, as well as from pathology reports at the Institute of Pathology at the same institution. Segmental ureterectomy was conducted in imperative (solitary kidney, chronic renal insufficiency, impaired renal function or parenchymal rarification of the contralateral kidney or American Society of Anesthesiologists score 4) or in elective cases, if the lesion was unifocally located in the distal ureter. Pathologic T-stages were uniformly adjusted according to the TNM 2009 classification system; tumour grade was assessed according to the WHO 1973 guidelines ([@bib10]; [@bib20]). Additionally, data on tumour site and location, presence or absence (not quantitatively assessed) of histologic tumour necrosis, surgical resection margins, as well as patients\' age and gender were retrieved from patients\' medical/pathological records as mentioned above. All laboratory data, including neutrophil and lymphocyte counts, were obtained during patients\' hospitalisation before surgery. The dNLR was calculated according to the original publication by [@bib16]) as follows: dNLR=neutrophil count to (white cell count−neutrophil count). Patients\' follow-up included a physical examination, cystoscopy and urinary cytology, as well as radiological assessment (CT or MRI) for at least 5 years, according to the current (2013) European Association of Urology guidelines ([@bib17]). No neoadjuvant treatment was administered. Patients\' time of death was obtained from the central registry of the Austrian Bureau of Statistics. Cancer-related death was coded as a cancer-specific event. All other deaths were considered as other-cause mortality. The median time of follow-up was calculated using the time to patients\' last follow-up or death.

Statistical analyses
--------------------

Primary study end points consisted of patients\' OS and CSS. Receiver operating characteristic (ROC) curve analysis was used to determine differences between the NLR and dNLR. The optimal cutoff values for the dNLR were determined by ROC analysis. The dNLR was subsequently correlated with clinicopathological features by the *χ*^2^ test. The association between the clinicopathological features and the dNLR with patients\' CSS and OS was analysed using Kaplan--Meier curves and compared by the log-rank test. In the multivariate Cox-regression analysis, the model was adjusted for prognostic clinicopathological factors that were statistically significantly associated with CSS and OS in univariate analyses. Hazard ratios (HRs) estimated from the Cox analysis are reported as relative risks with corresponding 95% confidence intervals (CIs). Harrell\'s concordance index (c-index) was used for the assessment of the predictive accuracy of the model in multivariable analyses, as well as to compare after supplementation by the dNLR ([@bib13]).

All statistical analyses were performed using the Statistical Package for Social Sciences version 20.0 (SPSS Inc., Chicago, IL, USA), MedCalc or STATA software. A two-sided *P*\<0.05 was considered statistically significant.

Results
=======

Overall, there were 107 (62.6%) male and 64 (37.4%) female subjects in the study cohort. The mean age of the study cohort at the time of surgery was 69±10.1 years. In 95 (55.6%) patients, the tumour was located in the renal pelvis and in 76 (44.4%) patients the tumour was located in the ureter. At the pathological examination, 79 (46.2%) patients showed a pT1 tumour and 92 (53.8%) patients had a muscle-invasive tumour or advanced disease state (pT2--4). Tumour grades were distributed as follow: G1--2 in 92 (53.8%) and G3--4 in 79 (46.2%) patients. Histologic tumour necrosis was noted in 21 (12.3%) patients. There were no significant differences in the distribution of clinicopathological factors between the 171 analysed cases and the 31 excluded cases ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The mean dNLR was 2.6±1.8. Seventy-nine (46.2%) patients died within the study period, of which 54 (31.6%) had a cancer-related death. The ROC curves, using CSS and OS as an end point for NLR and dNLR, are shown in [Supplementary Figures 1 and 2](#sup1){ref-type="supplementary-material"}. The ROC curves for NLR and dNLR were 0.603 (0.525--0.677) and 0.586 (0.508--0.660) for CSS (*P*=0.506) and 0.649 (0.572--0.720) and 0.629 (0.552--0.702) for OS (*P*=0.434), respectively. The statistically significant correlation between the NLR and dNLR was 0.833 (*P*\<0.001, Spearman correlation). Additionally, we analysed the relationship of the NLR and dNLR to other potential prognostic clinicopathological factors. Only for the dNLR, a statistically significant association (*P*=0.044) with higher tumour grade could be observed ([Table 1](#tbl1){ref-type="table"}). The median follow-up was 31 months (interquartile range 13--69 months).

To investigate whether the dNLR is associated with patients\' clinical outcomes, univariate and multivariate analyses were performed. Univariate analysis identified high pT-stage (pT-2--4, *P*\<0.001), high tumour grade (G1--2 *vs* G3--4, *P*\<0.001), the presence of histologic tumour necrosis (*P*\<0.001), as well as an increased dNLR (continuous variable *P*=0.024) as prognosticators of poor CSS, whereas gender, older (⩾65 yrs.) age, period of surgery, tumour site and tumour location were not associated with patients\' CSS in a statistically significant manner ([Table 2](#tbl2){ref-type="table"}).

[Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} show the Kaplan--Meier curves for patients\' OS, as well as for CSS, and reveal that an elevated (an optimal cutoff value was calculated by ROC analysis of ⩾1.5) dNLR represented a strong and robust factor for decreased survival rates at 10 years in UTUC patients in the cohort studied (log-rank *P*\<0.004 and \<0.002). To determine the independent prognostic significance of the dNLR for patients\' CSS, a multivariate analysis using a Cox proportional hazard model was performed. The model revealed that pT-stage (HR=2.34, 95% CI=1.14--4.80, *P*=0.021), tumour grade (HR=2.05, 95% CI=1.09--3.83, *P*=0.025), the presence of histologic tumour necrosis (HR=2.16, 95% CI=1.09--4.29, *P*=0.028), as well as the (continuously coded) dNLR (HR=1.16, 95% CI=1.01--1.35, *P*=0.045) were independent predictors of CSS ([Table 2](#tbl2){ref-type="table"}). Regarding OS, high (⩾65yrs.) age at the time of surgery (HR=2.02, 95% CI=1.13--3.60, *P*=0.017), muscle-invasive pT-stage (HR=1.97, 95% CI=1.12--3.44, *P*=0.018), as well as an elevated (⩾1.5) dNLR (HR=1.21, 95% CI=1.09--1.34, *P*\<0.001) were confirmed as independent prognosticators ([Table 2](#tbl2){ref-type="table"}). Harrell\'s c-index of the multivariate model for OS was 0.68 and 0.73 when dNLR was supplemented, whereas Harrell\'s c-index for CSS was 0.74 without and 0.75 with the dNLR supplemented.

Discussion
==========

The results of the present study clearly indicate that the pretreatment dNLR might be considered as a significant prognostic factor in UTUC patients, allowing to potentially better predicted survival after surgical treatment. The hypothesis that the inflammatory response might be heavily involved in the natural history of various human cancer types has been confirmed by several studies, as mentioned before, and as both the NLR and the dNLR have already been shown to be able to predict survival in different cancer types ([@bib16]; [@bib1]; [@bib3]; [@bib19]; [@bib21]). The combined index dNLR is derived from the assumption that the white cell count is made up primarily of lymphocytes and neutrophils, and, therefore, the white cell count minus the neutrophil count would be broadly similar to lymphocyte counts. [@bib16]) were the first to test the potential prognostic significance of the dNLR compared with the NLR alone in more than 12 000 patients with different cancer types. Both measures showed a similar prognostic value in a large cohort of unselected cancer patients. The authors hypothesised that the dNLR is broadly mixing two cell types, namely lymphocytes and monocytes, with possible opposing effects in terms of predictive value. In the normal range, the relative proportion of lymphocytes to monocytes is regarded to be ∼6 : 1. Even if there might be a fall in the absolute proportion of lymphocytes and an increase in the absolute proportion of monocytes in cancer patients, the white blood count minus monocytes is dominated by lymphocytes. Therefore, it seems highly likely that the dNLR represents a reasonable approximation of the NLR, and the potential error introduced by the presence of monocytes in the fraction is therefore likely to be small ([@bib16]).

In a recent study, [@bib1]) tested the effect of preoperatively assessed dNLR in patients with stages II and III colon cancer. In their study cohort, the dNLR represented an independent prognostic marker for patients\' OS and time to recurrence in patients with advanced colon cancer.

The potential prognostic role of the NLR in urological cancer types has so far been confirmed only in a few studies ([@bib6]; [@bib3]; [@bib14]). In our study, we confirmed that patients with a high preoperative NLR had a subsequently higher cancer-specific- as well as overall mortality after radical surgery for UTUC compared with those with a low preoperative NLR ([@bib3]). With the same aims we tested the prognostic role of the dNLR after radical surgery for UTUC. Our recent study clearly indicates that a high dNLR might be an independent predictor of survival in UTUC patients. To the best of our knowledge, this is the first study to evaluate the potential prognostic impact of pretreatment dNLR in UTUC patients with regard to CSS and OS. The ideal cutoff value in our study for dNLR was 1.5. Therefore, our results should be interpreted with caution, as the ideal threshold for the continuously coded dNLR was calculated by testing all possible thresholds that would discriminate between patients\' survival and cancer-related death by Cox proportional analyses. Furthermore, an ideal and generalisable dNLR threshold in UTUC has yet to be determined. In the present study, pathologic T-stage, tumour grade, the presence of histologic tumour necrosis and the (continuously coded) dNLR represented independent predictors of patients\' CSS. It has to be emphasised that currently pathologic T-stage represents the most important prognostic factor in UTUC in the largest published series ([@bib11]; [@bib8]). In the present study, we support the role of preoperatively available inflammatory parameters as useful potential biomarkers in UTUC, particularly because of low associated costs and easy accessibility. Nevertheless, our results should be interpreted with caution, as several potentially confounding factors are related to patients\' inflammatory responses, comorbidities, as well as to known study limitations such as retrospective design and data evaluation. A future validation of our findings in prospective multicentre series is warranted.
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###### Comparison between the dNLR and NLR and their association with clinicopathological variables in patients with upper tract urothelial carcinoma (*n*=171)

                                   **dNLR\<1.5**   **dNLR ⩾1.5**    ***P-*****value**  **NLR\<2.7**   **NLR ⩾2.7**    ***P-*****value**
  -------------------------------- --------------- --------------- ------------------- -------------- -------------- -------------------
  **Gender**                                                                                                         
  Female                           17 (9.9%)       47 (27.5%)             0.955        21 (12.3%)     43 (25.1%)            0.788
  Male                             28 (16.4%)      79 (46.2%)                          33 (19.3%)     74 (43.3%)               
  **Age at operation (yrs.)**                                                                                        
  \<65                             16 (9.4%)       38 (22.2%)             0.504        22 (12.9%)     32 (18.7%)            0.080
  ⩾65                              29 (17.0%)      88 (51.5%)                          32 (18.7%)     85 (49.7%)               
  **Tumour site**                                                                                                    
  Left                             30 (17.5%)      63 (36.8%)             0.054        34 (19.9%)     59 (34.5%)            0.126
  Right                            15 (8.8%)       63 (36.8%)                          20 (11.7%)     58 (33.9%)               
  **Tumour location**                                                                                                
  Ureter                           22 (12.9%)      54 (31.6%)             0.485        26 (15.2%)     50 (29.2%)            0.508
  Pelvis                           23 (13.5%)      72 (42.1%)                          28 (16.4%)     67 (39.2%)               
  **pT-stage**                                                                                                       
  pT1                              25 (14.6%)      54 (31.6%)             0.142        30 (17.5%)     49 (28.7%)            0.095
  pT2--4                           20 (11.7%)      72 (42.1%)                          24 (14.0%)     68 (39.8%)               
  **Tumour grade**                                                                                                   
  G1+G2                            30 (17.5%)      62 (36.3%)             0.044        35 (20.5%)     57 (33.3%)            0.050
  G3+G4                            15 (8.8%)       64 (37.4%)                          19 (11.1%)     60 (35.1%)               
  **Histologic tumour necrosis**                                                                                     
  No                               42 (24.6%)      108 (63.2%)            0.181        50 (29.2%)     100 (58.5%)           0.187
  Yes                              3 (1.8%)        18 (10.5%)                          4 (2.3%)       17 (9.9%)                

Abbreviations: dNLR=derived neutrophil--lymphocyte ratio; NLR=neutrophil--lymphocyte ratio.

###### Univariate and multivariate analyses of clinicopathological variables in patients with upper tract urothelial carcinoma (*n*=171)

                                   **Overall survival**   **Cancer-specific survival**                                                                                   
  -------------------------------- ---------------------- ------------------------------ ------------------- --------- ------------------- --------- ------------------- -------
  **Gender**                                                                                                           1 (Reference)       0.945                             
  Female                           1 (Reference)          0.523                                 n.d.           n.d.    0.98 (0.56--1.72)                    n.d.          n.d.
  Male                             1.17 (0.73--1.87)                                                                                                                         
  **Age at operation (yrs.)**                                                                                                                                            
  \<65                             1 (Reference)          0.004                             1 (Reference)      0.017   1 (Reference)       0.112            n.d.          n.d.
  ⩾65                              2.27 (1.29--3.99)                                      2.02 (1.13--3.60)            1.67 (0.89--3.13)                                     
  **Period of surgery**                                                                                                                                                  
  1990--1997                       1 (Reference)                                                                       1 (Reference)                                         
  1998--2004                       1.06 (0.50--2.21)      0.878                                 n.d.           n.d.    1.44 (0.56--3.64)   0.449            n.d.          n.d.
  2005--2012                       1.09 (0.64--1.85)      0.734                                                        1.70 (0.87--3.29)   0.116                             
  **Tumour site**                                                                                                                                                        
  Left                             1 (Reference)          0.291                                 n.d.           n.d.    1 (Reference)       0.136            n.d.          n.d.
  Right                            0.29 (0.81--1.99)                                                                   1.52 (0.88--2.64)                                     
  **Tumour location**                                                                                                                                                    
  Ureter                           1 (Reference)          0.035                             1 (Reference)      0.183   1 (Reference)       0.219            n.d.          n.d.
  Pelvis                           1.66 (1.04--2.66)                                      1.41 (0.85--2.35)            1.42 (0.88--2.50)                                     
  **pT-stage**                                                                                                                                                           
  pT1                              1 (Reference)          \<0.001                           1 (Reference)      0.018   1 (Reference)       \<0.001      1 (Reference)     0.021
  pT2--4                           2.93 (1.78--4.83)                                      1.97 (1.12--3.44)            3.86 (2.02--7.39)              2.34 (1.14--4.80)      
  **Tumour grade**                                                                                                                                                       
  G1+G2                            1 (Reference)          \<0.001                           1 (Reference)      0.134   1 (Reference)       \<0.001      1 (Reference)     0.025
  G3+G4                            2.29 (1.45--3.61)                                      1.48 (0.88--2.49)            3.07 (1.72--5.46)              2.05 (1.09--3.83)      
  **Histologic tumour necrosis**                                                                                                                                         
  No                               1 (Reference)          \<0.001                           1 (Reference)      0.203   1 (Reference)       \<0.001      1 (Reference)     0.028
  Yes                              2.95 (1.66--5.26)                                      1.50 (0.79--2.94)            4.06 (2.13--7.74)              2.16 (1.09--4.29)      
  **dNLR (continuously coded)**    1.25 (1.13--1.39)      \<0.001                         1.21 (1.09--1.34)   \<0.001  1.19 (1.02--1.38)   0.024      1.16 (1.01--1.35)   0.045

Abbreviations: 95% CI=confidence intervals; dNLR=derived neutrophil--lymphocyte ratio; HR=hazard ratio; n.d.=not done in multivariate analysis.
